E Nikiphorou1, S Ramiro2, D van der Heijde2, S Norton3, A Moltó4, M Dougados4, F van den Bosch5, R Landewé6. 1. Leiden University Medical Center, Leiden, The Netherlands, and King's College London, London, UK. 2. Leiden University Medical Center, Leiden, The Netherlands. 3. King's College London, London, UK. 4. Paris Descartes University, Hôpital Cochin. Assistance Publique-Hôpitaux de Paris, INSERM (U1153): PRES Sorbonne Paris-Cité, Paris, France. 5. VIB Inflammation Research Center, Ghent University, Ghent, Belgium. 6. Amsterdam Rheumatology Center, Amsterdam, and Zuyderland MC, Heerlen, The Netherlands.
Abstract
OBJECTIVE: Comorbidities add to the burden of disease and its complexity, and may prevent the achievement of treat-to-target goals. The objective of this study was to study the relationship between comorbidities and key disease outcomes in spondyloarthritis (SpA), namely function, work ability, and quality of life. METHODS: Patients from the multinational (22 countries), cross-sectional Assessment in SpondyloArthritis international Society (ASAS) Comorbidities in Spondyloarthritis study were included in the analysis, provided they fulfilled the ASAS criteria. Data on comorbidities based on both self- and physician-report were collected through questionnaires and were subsequently used to compute the Rheumatic Disease Comorbidity Index (RDCI). Univariable and multivariable (adjusted for relevant confounders) multilevel (with country as a random effect) linear or logistic (as appropriate) regression analyses were conducted to investigate the relationship between the RDCI and functional ability, work ability, and quality of life. RESULTS: In total, 3,370 of 3,984 recruited patients (85%) fulfilled the ASAS criteria: 66% were male, mean ± SD age was 43 ± 14 years, mean ± SD disease duration was 8.4 ± 9.5 years, and mean ± SD RDCI was 0.7 ± 1.1. At least 1 comorbidity was reported in 51% of patients; 9% had ≥3 comorbidities. RDCI was independently associated with a higher Bath Ankylosing Spondylitis Functional Index score (β = 0.37, 95% confidence interval [95% CI] 0.30, 0.43), lower EuroQol 5-domain questionnaire (β = -0.03, 95% CI -0.04, -0.02), less work employment (odds ratio [OR] 0.83, 95% CI 0.76, 0.91), higher absenteeism (OR 1.18, 95% CI 1.04, 1.34), and higher presenteeism (OR 1.42, 95% CI 1.26, 1.61). CONCLUSION: Comorbidities in SpA adversely influence physical function, work ability, and quality of life and are important to take into account in daily clinical practice.
OBJECTIVE: Comorbidities add to the burden of disease and its complexity, and may prevent the achievement of treat-to-target goals. The objective of this study was to study the relationship between comorbidities and key disease outcomes in spondyloarthritis (SpA), namely function, work ability, and quality of life. METHODS:Patients from the multinational (22 countries), cross-sectional Assessment in SpondyloArthritis international Society (ASAS) Comorbidities in Spondyloarthritis study were included in the analysis, provided they fulfilled the ASAS criteria. Data on comorbidities based on both self- and physician-report were collected through questionnaires and were subsequently used to compute the Rheumatic Disease Comorbidity Index (RDCI). Univariable and multivariable (adjusted for relevant confounders) multilevel (with country as a random effect) linear or logistic (as appropriate) regression analyses were conducted to investigate the relationship between the RDCI and functional ability, work ability, and quality of life. RESULTS: In total, 3,370 of 3,984 recruited patients (85%) fulfilled the ASAS criteria: 66% were male, mean ± SD age was 43 ± 14 years, mean ± SD disease duration was 8.4 ± 9.5 years, and mean ± SD RDCI was 0.7 ± 1.1. At least 1 comorbidity was reported in 51% of patients; 9% had ≥3 comorbidities. RDCI was independently associated with a higher Bath Ankylosing Spondylitis Functional Index score (β = 0.37, 95% confidence interval [95% CI] 0.30, 0.43), lower EuroQol 5-domain questionnaire (β = -0.03, 95% CI -0.04, -0.02), less work employment (odds ratio [OR] 0.83, 95% CI 0.76, 0.91), higher absenteeism (OR 1.18, 95% CI 1.04, 1.34), and higher presenteeism (OR 1.42, 95% CI 1.26, 1.61). CONCLUSION: Comorbidities in SpA adversely influence physical function, work ability, and quality of life and are important to take into account in daily clinical practice.
Authors: Sizheng Steven Zhao; Helga Radner; Stefan Siebert; Stephen J Duffield; Daniel Thong; David M Hughes; Robert J Moots; Daniel H Solomon; Nicola J Goodson Journal: Rheumatology (Oxford) Date: 2019-10-01 Impact factor: 7.580
Authors: Cristina Fernández-Carballido; María A Martín-Martínez; Carmen García-Gómez; Santos Castañeda; Carlos González-Juanatey; Fernando Sánchez-Alonso; Rosario García de Vicuña; Celia Erausquin-Arruabarrena; Javier López-Longo; María D Sánchez; Alfonso Corrales; Estefanía Quesada-Masachs; Eugenio Chamizo; Carmen Barbadillo; Javier Bachiller-Corral; Tatiana Cobo-Ibañez; Ana Turrión; Emilio Giner; Javier Llorca; Miguel A González-Gay Journal: Arthritis Care Res (Hoboken) Date: 2020-05-14 Impact factor: 4.794
Authors: Veerle Stouten; Sofia Pazmino; P Verschueren; Pavlos Mamouris; René Westhovens; Kurt de Vlam; Delphine Bertrand; Kristien Van der Elst; Bert Vaes; Diederik De Cock Journal: RMD Open Date: 2021-06
Authors: Casper Webers; Laura Vanhoof; Simon van Genderen; Liesbeth Heuft; Mart van de Laar; Jolanda Luime; Désirée van der Heijde; Floris A van Gaalen; Anneke Spoorenberg; Annelies Boonen Journal: RMD Open Date: 2018-06-27